Glick Gary D 4

What Happened
Gary D. Glick, President and Chief Executive Officer of Odyssey Therapeutics (ODTX), received a grant of 884,450 derivative shares on 2026-05-07 (reported 2026-05-11) at $0.00. On 2026-05-11 he recorded conversions of derivative securities: an acquisition of 27,386 common shares and dispositions of 100,000 and 166,116 derivative shares (these disposition entries are noted as "Derivative" on the Form 4). The award shows a $0.00 per-share price (no cash paid); the conversion/disposition entries list N/A prices.

Key Details

• Transaction dates: grant/award 2026-05-07 (reported 2026-05-11); conversions recorded 2026-05-11.
• Prices/values: Awarded 884,450 derivative shares @ $0.00 (total cash paid = $0); conversion/disposition entries shown with N/A prices.
• Shares reported converted/disposed on 5/11: 27,386 shares acquired; 100,000 and 166,116 shares disposed (derivative). Total disposed = 266,116.
• Shares owned after the transactions: not specified in the provided summary.
• Filing timeliness: Form filed 2026-05-11 for transactions with a period ending 2026-05-07 (no indication of a late filing).
• Remarks: Reporting person listed as President and Chief Executive Officer.

Context

• The filing’s footnotes explain these were conversions of preferred/derivative securities in connection with the issuer’s IPO: Series C and Series D preferred shares converted into common stock on a 1-for-9.7170 basis for no additional consideration (footnotes F1–F3). A 1-for-9.7170 reverse split was also given effect prior to the IPO.
• The 884,450 award appears to be subject to time-based vesting: an option/award vests in 48 equal monthly installments with the first installment scheduled to vest on June 7, 2026 (footnote F4).
• These entries reflect corporate/IPO-related conversions and an awarded derivative position rather than open-market purchases or cash sales; they should be read as capital-structure/compensation actions rather than a straightforward buy/sell signal.